Rx Compliance Enforcement Is Moving Away From “FDA” Cases, Sheehan Says
Executive Summary
CAMBRIDGE, Mass.-Due to FDA's diminishing influence over the direction of pharmaceutical regulatory enforcement, a comprehensive understanding of the compliance concerns for drug products should focus on existing case law to understand the dynamics of the enforcement landscape, New York Medicaid Inspector General James Sheehan said